ICN was named in two new shareholder lawsuits.

For the second time in less than a week, ICN Pharmaceuticals Inc. has become the target of class-action shareholder lawsuits accusing the Costa Mesa drug maker of illegally inflating its stock price. In two suits filed Wednesday in Los Angeles federal court, ICN, its Viratek Inc. subsidiary, ICN Chairman Milan Panic and ICN Director Robert A. Smith are accused of misrepresenting the potential of the drug Virazole, considered a possible AIDS medication. An attorney for ICN declined to comment.